| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8623795 | Seminars in Arthritis and Rheumatism | 2018 | 5 Pages |
Abstract
Case reports on the use of biological agents have yielded mixed results. The diversity of the symptoms may be due to functional differences in NOD2 mutations. For BS patients with fever, lymphadenopathy and hepatosplenomegaly, Tocilizumab may be a better choice.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Li MD, Min PhD, Dongbin MD, Yanmin MD, Xiaolong MD, Yao MD, Zhixun MD, Leilei MD, Jungen MD, Yanke MD, Shengyun PhD, Zhaohui PhD, Guanmin PhD, Quancheng PhD,